Homicsko, K.
52  Ergebnisse:
Personensuche X
?
2

11P Association of VISTA-expressing CD66b-positive neutroph..:

Homicsko, K. ; Zygoura, P. ; Tissot, S....
Immuno-Oncology and Technology.  16 (2022)  - p. 100116 , 2022
 
?
3

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni, E. ; Wicky, A. ; Bouchaab, H....
European Journal of Cancer.  149 (2021)  - p. 153-164 , 2021
 
?
 
?
6

Cancer Immunotherapy: A Simple Guide for Interventional Rad..:

Digklia, A. ; Duran, R. ; Homicsko, K....
CardioVascular and Interventional Radiology.  42 (2018)  9 - p. 1221-1229 , 2018
 
?
7

Phase I trial of the oral smoothened inhibitor sonidegib in..:

Stathis, A. ; Hess, D. ; von Moos, R....
Investigational New Drugs.  35 (2017)  6 - p. 766-772 , 2017
 
?
 
?
 
?
 
?
12

Salsolinol is a Putative Endogenous Neuro‐intermediate Lobe..:

Tóth, B. E. ; Homicskó, K. ; Radnai, B....
Journal of Neuroendocrinology.  13 (2001)  12 - p. 1042-1050 , 2001
 
?
13

Response and Resistance to Trametinib in MAP2K1-Mutant Trip..:

Krebs, F.S ; Moura, B ; Missiaglia, E...
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms24054520.  , 2023
 
?
14

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity res..:

Tichet, M ; Wullschleger, S ; Chryplewicz, A...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.immuni.2022.12.006.  , 2023
 
?
15

Deep and lasting response and acquired resistance to BRAFV6..:

Anchisi, S ; Wolfer, A ; Bisig, B...
info:eu-repo/semantics/altIdentifier/doi/10.1080/15384047.2023.2193116.  , 2023
 
1-15